[1] Stockdale A J, Kreuels B, Henrion M Y R, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis[J]. J Hepatol, 2020,73(3):523-532.
[2] John B V, Bastaich D, Amoli M M, et al. Association of HDV infection and HCC, hepatic decompensation, and all-cause and liver-related death in a national cohort[J]. Hepatology, 2025,81(6):1822-1835.
[3] Rizzetto M, Canese M G, Aricò S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977,18(12):997-1003.
[4] Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis[J]. 2020,221(10):1677-1687.
[5] Wang Y, Shen G, Lu R, et al. The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China[J]. Int J Infect Dis, 2024,140:70-77.
[6] Chen S, Ren F, Huang X, et al. Underestimated prevalence of HIV, Hepatitis B Virus (HBV), and hepatitis D virus (HDV) triple infection globally: systematic review and meta-analysis[J]. JMIR Public Health Surveill. 2022,8(11):e37016.
[7] Papatheodoridis G, Mimidis K, Manolakopoulos S, et al. HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patients[J]. Liver Int. 2023,43(9):1879-1889.
[8] Da B L, Rahman F, Lai W C,et al. Risk factors for delta hepatitis in a North American cohort: who should be screened?[J]. Am J Gastroenterol. 2021,116(1):206-209.
[9] 余姣,万谟彬. 慢性乙型肝炎患者中丁型肝炎病毒共感染的筛查与治疗研究进展[J]. 肝脏. 2024,29(07): 762-766.
[10] Patmore L A, Spaan M, Agarwal K, et al. Prediction of hepatocellular carcinoma and liver-related events in anti-hepatitis D virus-positive individuals[J]. Clin Gastroenterol Hepatol. Published online October 9, 2024.
[11] Terrault N A, Lok A S F, McMahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology. 2018,67(4):1560-1599.
[12] Wong R J, Jain M K, Niu B, et al. Hepatitis delta virus testing and prevalence among chronic hepatitis B patients across three U.S. safety-net health systems[J]. Clin Gastroenterol Hepatol. Published online October 24, 2024.
[13] 邹怀宾,姚乘轩,段钟平,等. 丁型肝炎流行病学的研究进展及我国的主要挑战[J]. 中国临床研究. 2025,38(2): 242-246.
[14] Palom A, Rando-Segura A, Vico J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D[J]. JHEP Rep. 2022,4(10):100547.
[15] Elsaid M I, Li Y, John T, et al. Economic and health care burdens of hepatitis delta: a study of commercially insured adults in the United States[J]. Hepatology. 2020,72(2):399-411.
[16] Abdrakhman A, Ashimkhanova A, Almawi W Y. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis[J]. Antiviral Res. 2021,185:104995.
[17] Etzion O, Hamid S, Lurie Y, et al. Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial[J]. Hepatology. 2023,77(6):2093-2103.
[18] Degasperi E, Anolli M P, Jachs M, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis[J]. J Hepatol. 2025,82(6):1012-1022.
[19] Lampertico P, Bogomolov P O, Chulanov V, et al. Phase 2 randomised study of bulevirtide as monotherapy or combined with Peg-IFNα-2a as treatment for chronic hepatitis delta[J]. Liver Int. 2025,45(2):e70008.
[20] Yurdaydin C, Keskin O, Yurdcu E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis[J]. Hepatology. 2022,75(6):1551-1565. |
